BALTIMORE, June 14, 2012 /PRNewswire/ -- AmeritoxSM, the nation's leader in pain medication monitoring, announced today that the Baltimore, MD, Federal Court issued a temporary restraining order against Millennium Laboratories. Following is the language of the Temporary Restraining Order issued by the Court on Wednesday, June 13, 2012:
"Ameritox has filed an Emergency Motion for a Temporary Restraining Order. Docket No. 306. Ameritox's counsel docketed the motion and served a copy on Millennium's counsel. The lateness of the hour precluded the Court from convening a hearing today. The Court will, however, hold a hearing tomorrow. Counsel shall be prepared to begin at 11:00 a.m., although the start of the hearing will be determined by the mutual availability of Judge Gallagher and myself.
Ameritox's motion concerns a press release ("Press Release") that Millennium issued concerning the litigation. The Court has not had the opportunity to parse the press release and to hear the arguments of counsel as to its propriety.
Nevertheless, Ameritox's motion raises a serious issue concerning publicity given to matters that were sealed and remain under seal. Accordingly, the Court hereby issues the following Temporary Restraining Order. The Court has the authority to issue the Order because this case remains open, the Court has jurisdiction over any potential violation of its sealing order, and the Court also has jurisdiction over the Consent Order. The Court finds that this Order meets all of the requirements of Rule 65(b), including the likelihood of irreparable injury to Ameritox, for issuance of a Temporary Restraining Order before hearing the arguments of opposing counsel.
It is this 13th Day of June, 2012, hereby ORDERED as follows:
- Millennium shall remove the Press Release from its web site;
- Millennium sales representatives are hereby enjoined from using the Press Release in sales presentations or communications;
- Until further order, Millennium shall submit for approval to the undersigned or to Judge Gallagher all public statements concerning this litigation; and
- As the first order of business at tomorrow's hearing, the Court will hear from counsel concerning the means by which statements appearing in the Press Release have been disseminated and the measures taken by Millennium to comply with this Order."
Ameritox is the nation's leader in Pain Medication Monitoring Solutions®, offering specialized laboratory testing and reporting services. Ameritox's expertise and innovative science provide physicians with insights and support to enhance and optimize the care of chronic pain patients. Ameritox offers the most thorough pain medication monitoring lab process – Rx GuardianSM – with Rx Guardian CD(SM), the only pain medication screening with a proprietary normalization algorithm and a reference database of pain patients assessed for medication adherence. Patient results are compared against this database, helping physicians assess whether patients are taking their pain medications correctly. Monitoring through urine drug testing helps physicians make more informed clinical decisions and manage the risks and complexities associated with prescribing pain medications. Ameritox is headquartered in Baltimore, Md. with laboratory facilities in Midland, Texas and Greensboro, N.C. Ameritox can be found online at www.ameritox.com, on Twitter @Ameritox, or on Facebook at facebook.com/ameritox.
© 2012 Ameritox Ltd. All rights reserved. AMERITOX, the AMERITOX logos, AMERITOX AUTOREMINDER, AMERITOX MEDICATION MONITORING SOLUTIONS, AMERITOX UNIVERSITY, PAIN MEDICATION MONITORING SOLUTIONS, POWERED BY YOUR NEED TO KNOW and PROTECT YOUR PATIENTS. PROTECT YOUR PRACTICE. RX GUARDIAN, RX GUARDIAN CD, and RX GUARDIAN AUTOREMINDER are trademarks of Ameritox.
Director of Communications